suPAR is a prognostic tool reflecting the extent of activation of our immune system non-specific to any individual disease. 

This is the key advantage: The suPAR-level is, across diseases, directly linked to morbidity and mortality and therefore can be used to discriminate between non-survivors and survivors.

In Acute Triage, this will allow the hospital to:

  • Identify, treat and hospitalize those first who need it most:
    Ill patients with inflammation associated with an increased disease severity, readmission and mortality risk (elevated suPAR-level).
  • Identify those who can be discharged following treatment because their prognosis is good (low suPAR-level), which will
    • Shorten the average patient-length-of-stay
    • Free up beds in the Emergency Department
    • Lead to significant cost savings for the hospital

Please find more information about the suPARnostic® products here.

suPAR in Clinical Use

suPAR is truly a novel biomarker and the concept of adding the prognostic information of patient risk status gained from measuring suPAR to clinical decision making is starting to be applied in medical practices.

The suPAR level is associated with presence, severity and progression of disease, and in unselected patients, suPAR is one of the strongest prognostic biomarkers available to date.

suPARnostic® is developed to measure the amount of suPAR protein in human blood. If an individual's suPARnostic® level is very high, there is an increased risk of a negative outcome (e.g. mortality). Appropriate treatment should result in a lowered suPARnostic® level.

suPARnostic® can improve the way seemingly low risk patients are managed - a low suPAR level helps avoid time and resources spent on further investigations, an elevated suPAR level is an indication that the patient is at higher risk of not surviving and it should be further investigated if this is caused by one or more developing diseases.

By measuring an individual's suPARnostic® level, the patients risk of non-survival will be determined, allowing the doctor to prioritize selection of treatment and monitoring.